Align Technology, Inc. ALGN
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, Align Technology, Inc. gets an algorithmic score of 48/100. It trades at 144.01 $, with a bearish technical trend (RSI 36.3) and 39.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
- Low valuation (P/E 11.5).
Weaknesses
- High beta (1.43): amplifies index moves.
Fundamentals
| P/E | 25.18 |
| Forward P/E | 11.52 |
| PEG | 0.62 |
| P/B | 2.42 |
| EV/EBITDA | 9.99 |
| P/S | 2.47 |
| ROE % | 10.15 |
| ROA % | 7.56 |
| Gross margin % | 70.74 |
| Operating margin % | 18.25 |
| Net margin % | 9.99 |
| Revenue growth % (y/y) | 4.30 |
| Earnings growth % (y/y) | -12.10 |
| Revenue CAGR % | 2.61 |
| Earnings CAGR % | 4.31 |
| Debt/Equity % | 2.85 |
| Current ratio | 1.40 |
| FCF yield % | 4.80 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -8.6 % |
| 3 months | -14.6 % |
| 6 months | -13.4 % |
| YTD | -7.7 % |
| 1 year | +14.1 % |
| 3 years | -51.8 % |
| 5 years | -79.7 % |
Risk
| 1-year volatility | 39.5 % |
| Beta | 1.43 |
| 5-year max drawdown | -82.8 % |
| Sharpe 1A | 0.43 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.